OKYO Insider Trading Activity and SEC Form 4 Filings
OKYO insider trading summary
Over the past 12 months, insiders at OKYO Pharma Ltd (OKYO) reported 7 open-market purchases worth $136K by 6 insiders and no sales on SEC Form 4. Net insider buying was $136K.
Latest OKYO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 27, 2026 | Rajkumar V. Patil | Chief Scientific Officer | Buy | $5K (3,363 @ $1.49) |
| Jul 22, 2026 | Robert John Dempsey | Chief Executive Officer | Buy | $23K (15,000 @ $1.54) |
| Jul 21, 2026 | John P Brancaccio | Director | Buy | $7K (5,000 @ $1.48) |
| Jul 21, 2026 | Flavio Mantelli | Chief Medical Officer | Buy | $28K (20,000 @ $1.40) |
| Jul 21, 2026 | Gary S Jacob | Chief Development Officer | Buy | $5K (3,500 @ $1.40) |
| Jul 21, 2026 | Gabriele M Cerrone | Director | Buy | $33K (22,500 @ $1.45) |
| Jul 20, 2026 | Gabriele M Cerrone | Director | Buy | $35K (25,000 @ $1.40) |
| Sep 15, 2023 | John P Brancaccio | Director | Buy | $25K (16,670 @ $1.50) |
| May 19, 2022 | Gabriele M Cerrone | Non-Executive Chairman | Buy | $150K (37,500 @ $4.00) |
| May 19, 2022 | Gary S Jacob | Chief Executive Officer | Buy | $50K (12,500 @ $4.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.